Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Women with IBD may be at increased risk for developing cervical cancer

Women with inflammatory bowel disease (IBD) may be at increased risk of cervical dysplasia and cancer, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

27 Mar 2015

Minimally-invasive surgery offers long-term cost savings for healthcare system, less trauma for patients

Adding to the clinical benefits and improved patient outcomes associated with minimally-invasive surgery (MIS), Medtronic plc today highlighted new data demonstrating that patients who underwent minimally invasive colon resection procedures were able to leave the hospital faster, visit their doctors less for follow up care and take fewer medicines than those who underwent open surgery.

27 Mar 2015

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients’ needs and concerns.

17 Mar 2015

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Professor Raja Atreya from Medical Clinic 1 of the Erlangen University Hospital has won the 60,000€ Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers for 2015. With his innovative diagnostic method, physicians can predict the clinical response of an expensive treatment of Crohn's disease which is associated with potential side effects.

17 Mar 2015

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA).

13 Mar 2015

The Medical Minute highlights risk and symptoms of IBD in children

Occasional stomach aches are part of life. But when they continue for more than a few weeks, come back often or are accompanied by bloody stools and additional symptoms, the cause could be inflammatory bowel disease, or IBD.

13 Mar 2015

Young immigrants to Canada at greater risk of developing IBD

The younger a person is when they immigrate to Canada, the higher their risk of developing inflammatory bowel disease (IBD), and its major subtypes Crohn's disease and ulcerative colitis, according to a study by researchers at the University of Ottawa, the Institute for Clinical Evaluative Sciences and the Children's Hospital of Eastern Ontario.

11 Mar 2015

Key questions about colorectal cancer answered

Colorectal cancer is the fourth most common cancer in the U.S., with more than 136,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

4 Mar 2015

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers, which are added to most processed foods to aid texture and extend shelf life, can alter the gut microbiota composition and localization to induce intestinal inflammation that promotes the development of inflammatory bowel disease and metabolic syndrome, new research shows.

26 Feb 2015

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars.

26 Feb 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.

26 Feb 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.

25 Feb 2015

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

23 Feb 2015

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

23 Feb 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse.

23 Feb 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.

19 Feb 2015

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Inflammatory bowel diseases (IBDs), including Crohn disease and ulcerative colitis, are hard to completely cure. Globally, IBDs affect more than 4 million people, today. However, Professor Soichi Tanabe (Graduate School of Biosphere Science, Hiroshima University) and his collaborators have demonstrated that 10-hydroxy-cis-12-octadecenoic acid (HYA), a gut microbial metabolite of linoleic acid, has a suppressive effect on intestinal inflammation.

19 Feb 2015

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Women with IBD may be at increased risk for developing cervical cancer

Minimally-invasive surgery offers long-term cost savings for healthcare system, less trauma for patients

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Samsung Bioepis submits second biosimilar candidate MAA to EMA

The Medical Minute highlights risk and symptoms of IBD in children

Young immigrants to Canada at greater risk of developing IBD

Key questions about colorectal cancer answered

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Scientists find new links between inflammation and tissue regeneration

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Actavis files ANDA to market Budesonide Extended-release Tablets

Shire announces acquisition of Meritage Pharma

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in